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INTRODUCTION
Most hepatitis B virus (HBV) infections occur during deliv-
ery or infancy, and follow a chronic course among patients in
Korea and other Asian countries (1, 2). The natural course of
chronic hepatitis B (CHB) is determined by interactions be-
tween the host immune system and the virus. HBeAg sero-
conversion occurs during the immune clearance stage in 5-
15% of patients every year. Once seroconversion is maintained
and the serum HBV DNA level decreases markedly, the ala-
nine transaminase (ALT) level normalizes, and the inflamma-
tory reaction in the liver subsides (3). Whether spontaneous
or due to therapy, HBeAg seroconversion is not only an impor-
tant transition point throughout the natural course of chronic
HBV infection but is also an essential factor in the clinical
course of the disease. It is also a marker for evaluating thera-
pies that involve interferon or lamivudine. In some patients,
HBeAg-negative CHB is found after seroconversion, and HBV
continues to proliferate, causing further liver damage and
leading to an increased risk of liver cirrhosis and cancer (4,
5). However, there are many cases of HBeAg-negative CHB
that are difficult to differentiate from the inactive HBsAg
carrier state due to frequent changes in the ALT levels (6).
In HBeAg-negative CHB with intermittent elevation of
ALT, the amount of serum HBV DNA increases just prior to
the rise in ALT. Ongoing HBV replication triggers immune
responses, causing liver injury. Knowledge of the minimum
amount of HBV needed to produce continuous liver damage
is important for a better understanding of the natural course
of the disease and of the cutoff value for clinical differentiation
of HBeAg-negative CHB from the inactive HBsAg carrier
state (7-12). Value of serum HBV DNA levels as determined
by the hybridization method is limited, because assay sensitiv-
ity is as low as 105 to 106 copies/mL. In this study, we used a
sensitive PCR-based assay to compare serum HBV DNA lev-
els at different clinical stages of chronic HBV infection (13).
The purpose of this study was to determine the serum HBV
DNA level that would differentiate HBeAg-negative CHB
patients from inactive HBsAg carriers.
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Serum Hepatitis B Virus (HBV) DNA Levels at Different Stages of
Clinical Course in Patients with Chronic HBV Infection in an Endemic
Area
The aims of this study were to investigate serum hepatitis B virus (HBV) DNA levels
at different clinical stages in patients with chronic HBV infection, and to determine
the serum HBV DNA level that discriminated HBeAg-negative chronic hepatitis B
(CHB) cases from inactive HBsAg carriers. In all, 222 patients, encompassing 68
HBeAg-positive CHB patients (HBeAg-positive, ALT-elevation), 89 HBeAg-negative
CHB patients (HBeAg-negative, ALT-elevation), and 65 inactive HBsAg carriers
(HBeAg-negative, ALT-normal), were tested. The ALT levels had been tested more
than twice during the previous six months, and the serum HBV DNA levels were
quantified by a polymerase chain reaction-based assay. The serum HBV DNA levels
of the HBeAg-negative patients were significantly lower than those of the HBeAg-
positive patients (median 2.7×10
4 vs. 1.6×10
8 copies/mL; p=0.000). In addition,
the HBV DNA levels of the HBeAg-negative CHB patients were significantly high-
er than those of the inactive HBsAg carriers (median 2.2×10
5 vs. 3.2×10
3 copies/
mL; p=0.000). The optimal HBV DNA level for discriminating HBeAg-negative CHB
cases from inactive HBsAg carriers was 2.0×10
4 copies/mL. The serum HBV DNA
levels were lower than the cutoff value in 72.3% (47/65) of the inactive HBsAg car-
riers, and in 31.5% (28/89) of the HBeAg-negative CHB patients. The serum HBV
DNA levels differed significantly between these two groups. However, the levels in
the two groups overlapped extensively, preventing the definition of a differentiation
cut-off value.
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MATERIALS AND METHODS
Subjects
Of 434 consecutive chronic HBV-infected patients, 253
patients who did not have a history of notable alcohol intake
(alcohol consumption of >40 g/wk) and who had not under-
gone anti-viral therapy during the previous six months were
chosen. Any patients who were co-infected with HCV were
excluded, as were 31 HBeAg-positive patients with normal
ALT levels. In all, 222 chronic HBV-infected patients were
studied retrospectively. This group consisted of 68 HBeAg-
positive CHB patients (HBeAg-positive, ALT elevation), 89
HBeAg-negative CHB patients (HBeAg-negative, ALT ele-
vation), and 65 inactive HBsAg carriers (HBeAg-negative,
ALT normal). All of the patients’ ALT levels had been tested
more than twice during the previous six months.
Liver Function, Viral Marker Test and The Quantita-
tion of HBV DNA
The Hitachi 7600 Series automatic biochemical analyzer
(Hitachi, Tokyo, Japan) was used for the liver function test. The
Abbott Axsym System (Abbott Laboratories, Abbott Park, IL,
U.S.A.) was used to check for viral markers. Quantitation of
HBV DNA was performed using the automated Cobas
Amplicor HBV MonitorTM (Roche, Basel, Switzerland),
which is as sensitive as 200 copies/mL (14, 15).
Purification of HBV DNA and Sample Preparation
Immediately after patient sampling, the blood sample was
stored in a refrigerator, clotted for 1 hr, and the serum was
centrifuged at 3,000 rpm for 5 min. The serum was then stored
at -70℃. The HBV DNA was processed from 100  L of serum
by manual virion lysis and neutralization, and the DNA was
precipitated with polyethylene glycol. The prescribed amounts
of quantization standard (QS) particles were added to each
sample and sample preparation, amplification reaction, and
detection process, for use as markers in the quantitative study
of the HBV DNA.
PCR Amplification and Quantification of HBV DNA
The processed sample (50  L, equivalent to 22  L of serum)
was added to the 50- L mixture in an amplification test tube
(labeled A), and inserted into the Cobas analyzer. The 104-
bp fragment, which represents the highly conserved preserved
precore-core component, was amplified using one biotinylat-
ed template (HBV-104UB) and one non-biotinylated template
(HBV-104D). The target HBV DNA QS was amplified using
the same template that was used to generate the 104-bp ampli-
con.
After 30 cycles of amplification, denaturation solution was
added automatically to tube A, in order to denature chemi-
cally the HBV and QS amplicons into single-stranded DNA
molecules. The denatured amplicons were serially diluted in
several detection glasses (labeled D) for quantitation across a
broad dynamic range. Magnetic beads were added to each of
the D glasses prior to hybridization with amplicon-labeled
biotin, using specific oligonucleotides probe at the surface of
the target HBV and QS sequence. After hybridization, the
magnetic beads were washed by the Cobas analyzer. Avidin-
horseradish peroxidase complex and TMB (3,3′ ,5,5′ -tetram-
ethyl benzidine) were added to form a pigment complex that
had a light absorbance of 660 nm (A).
Within the linear range of the test (2×102-2×105 copies/
mL), the light absorbance of each glass (A) correlated with the
quantity of HBV DNA or QS amplicon. The Cobas analyzer
multiplied the light absorbance level in glass D by the ampli-
con dilution factor to produce the total light absorbance. The
level of HBV DNA in each sample was calculated by the fol-
lowing equation (i.e., the ratio of the total light absorbance
of the HBV DNA to the total QS light absorbance and the
quantity of QS particles added):
HBV DNA/mL=Total HBV A660/Total QS A660×Added
QS copies×45
where the total HBV A660 and total QS A660 values were
calculated from the total light absorbances of HBV and QS,
respectively; the added QS copies in the PCR mixture equalled
the number of QS copies (kit-specific); and 45 was the num-
ber of copies per PCR, which was converted to the number
of copies per mL.
Statistics
Statistical analysis was carried out using the SPSS ver. 10.0
for Windows software (SPSS Inc., Chicago, IL, U.S.A.). The
HBV DNA level of each group was expressed as the median
value and range, while other clinical and laboratory values were
expressed as means±the standard deviation. The differences
*Chi-square test; 
� ANOVA.
Group
HBeAg (+)
CHB
HBeAg (-)
CHB
Inactive
HBsAg 
carrier
p value
No. (%) 68 (26.9) 89 (35.2) 65 (25.6)
Sex (M/F) 52/16 67/22 38/27 0.038*
Age (yr) 36±14 45±11 38±13 0.000
�
Chronic 51/17 22/67 45/20 0.000*
hepatitis/Cirrhosis
AST (IU/L) 109±106 95±103 27±11 0.000
�
ALT (IU/L) 173±212 112±114 23±8 0.000
�
Total bilirubin 1.4±2.6 1.9±3.8 1.0±0.6 0.125
�
(mg/dL)
Albumin (g/dL) 4.0±0.6 4.0±0.8 4.3±0.5 0.002
�
PT (INR) 1.13±0.1 1.3±0.6 1.0±0.2 0.323
�
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between groups were analyzed using the chi-square test,
ANOVA, and Mann-Whitney U test. An ROC curve was
used to determine the cut-off concentration of HBV DNA
that differentiated HBeAg-negative CHB cases from inactive
HBsAg carriers.
RESULTS
Clinical Features of Patients
The mean age of the patients was 40±13 yr (mean±stan-
dard deviation), ranging from 7 to 69 yr. There were 157 male
and 65 female patients. Liver cirrhosis was also present in 104
chronic hepatitis patients. The clinical and laboratory features
of each group are shown in Table 1.
Serum HBV DNA Levels
Serum HBV DNA was detected in all (68/68) of the patients
with HBeAg-positive CHB, in 94.4% (84/89) of the HBeAg-
negative CHB patients, and in 89.2% (58/65) of the inactive
HBsAg carriers.
The median serum HBV DNA level of the HBeAg-posi-
tive CHB patients was significantly higher than that of the
HBeAg-negative CHB patients (1.6×108 copies/mL vs. 2.7
×104 copies/mL; p=0.000).
The median serum HBV DNA level of the inactive HBsAg
carriers was 3.2×103 copies/mL (range: 2.0×102-9.2×106),
which was significantly lower than the median value for the
HBeAg-negative CHB patients (2.2×105 copies/mL; range:
2.0×10
2-7.5×10
10) (p=0.000; Fig. 1).
The cutoff value for the serum HBV DNA level that dif-
ferentiated between HBeAg-negative CHB cases and inactive
HBsAg carriers was set at 2.0×104 copies/mL on the ROC
curve, with 70.8% sensitivity and 72.3% specificity (Fig. 2).
In this case, 27.7% (18/65) of the inactive HBsAg carriers were
above the cut-off level, and 31.5% (28/89) of the HBeAg-neg-
ative CHB cases were below the level.
DISCUSSION
The aims of this study were to investigate serum HBV DNA
levels at different clinical stages in patients with chronic hep-
atitis B virus infection, and to determine the serum HBV DNA
level that would allow the discrimination of HBeAg-negative
chronic hepatitis B patients from inactive HBsAg carriers in
an endemic area. According to the results of this study, the
median serum HBV DNA level for the HBeAg-negative pa-
tients was approximately two logs lower than that for the
HBeAg-positive patients, regardless of ALT levels. The rea-
son that the HBeAg-negative patients showed higher serum
HBV DNA levels than in previous studies is related to differ-
ences in the target patient groups (16, 17). The previous stud-
ies included mainly inactive HBsAg carriers. In contrast, this
*Mann-Whitney U test. Ina.: Inactive.
Group
HBV DNA (copies/mL)
Median Range
Log
[HBV DNA]
p value*
HBeAg (+) 1.6×10
8 3.9×10
2-9.1×10
10 6.7±1.3
HBeAg (-) 2.7×10
4 2.0×10
2-7.5×10
10 4.3±1.8
0.000
HBeAg (+) CHB 1.6×10
8 3.9×10
2-9.1×10
10 6.7±1.3
HBeAg (-) CHB 2.2×10
5 2.0×10
2-7.5×10
10 4.9±1.8 0.000
Ina. HBsAg carrier3.2×10
3 2.0×10
2-9.2×10
6 3.5±1.5
Table 2. Serum HBV DNA levels in each patient group
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Fig. 1. Serum HBV DNA levels, which are shown as Log[HBV
DNA], in HBeAg-positive CHB patients (Group I), HBeAg-nega-
tive CHB patients (Group II), and inactive HBsAg carriers (Group
III). *95% confidence interval.
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Fig. 2. ROC curve for determining the HBV DNA level that discrim-
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study included not only inactive HBsAg carriers, but also
HBeAg-negative CHB patients.
The features of the inactive HBsAg carrier state are known
to include normal ALT, mild liver damage, and lower risk of
progression to liver cirrhosis, despite a small risk increase for
liver cancer (18). HBeAg-negative CHB has the characteris-
tics of active HBV proliferation and progressive liver damage
after seroconversion (6). Over the natural course of chronic
hepatitis B, the diagnostic criteria for the inactive HBsAg
carrier state are as follows: HBsAg positivity, HBeAg nega-
tivity, normal ALT, and HBV DNA concentration of <105
copies/mL (3). However, the cut-off level for the HBV DNA
is an arbitrary value, as proposed at the National Institute of
Health Workshop, to differentiate HBeAg-negative CHB cases
from inactive HBsAg carriers. In this study, serum HBV DNA
was detected in 89.2% of the inactive HBsAg carriers, and
the median level was 3.2×103 copies/mL, which is signifi-
cantly lower than the median value (2.2×105 copies/mL) for
HBeAg-negative CHB cases. Most of the serum HBV DNA
levels for HBeAg-negative CHB cases were below the detec-
tion levels for HBV DNA quantitation by non-PCR based
methods, which include hybrid capture, branched DNA sig-
nal amplification, and spot hybridization, which have lower
limits of detection between 105 and 106 copies/mL (6).
The optimal cut-off value that allowed patient discrimina-
tion was 2.0×104 copies/mL, although the accuracy associ-
ated with the adoption of this value was similar to that obtained
with the known cut-off value of 105 copies/mL. With 2.0×
104 copies/mL being set as the cut-off value, 27.7% (18/65) of
the inactive HBsAg carriers were above this level, and 31.5%
(28/89) of the HBeAg-negative CHB patients were below
this level. On the other hand, a cut-off value of 105 copies/mL
resulted in 20.0% (13/65) of the inactive HBsAg carriers being
above the cut-off level, and 40.4% (36/89) of the HBeAg-neg-
ative CHB patients being below. The result for the HBeAg-
negative CHB patients was consistent with that of a recent
study by Chu et al. (19), in which a cutoff value of 105 copies/
mL excluded 45% of HBeAg-negative CHB patients when
testing was performed only at the time of presentation. Since
many HBeAg-negative CHB patients show highly variable
patterns of disease activity, a wide distribution of HBV DNA
levels around the arbitrary cut-off value is expected at this stage
(20). These results show that it is difficult to define a single
serum HBV DNA cut-off level that permits differentiation
of HBeAg-negative CHB cases from inactive HBsAg carri-
ers to use as a guideline in treating HBeAg-negative CHB
patients. In contrast to our results, Chu et al. (19) showed that
an HBV DNA value of >105 copies/mL excluded all of the
inactive carriers, a finding that was supported by the work of
Martinot-Peignoux et al. (21), who showed that the median
serum HBV DNA level in inactive HBsAg carriers was 1,300
copies/mL, and that 98% of the HBV DNA samples were <105
copies/mL. The HBV DNA levels of the inactive HBsAg car-
riers in that study were similar to those observed in the pre-
sent study. However, the median value was lower, and the range
was narrower. This discrepancy may have resulted from dif-
ferences in the follow-up periods, rather than differences in the
selection of patients, since Chu et al. (19) also studied Asian
patients.
HBV infection in Asians occurs mainly in early childhood.
After more than 20 yr of immune tolerance, the immune clear-
ance phase follows for a variable period of time. In many pat-
ients, HBV may continue to replicate after HBeAg serocon-
version and cause liver damage. There have been many cases
of severe liver damage, including cirrhosis with slow progres-
sion, even among inactive HBsAg carriers (22-24). The inci-
dence of HBeAg-negative CHB is much higher in Asia than
in Western countries (25-27). In many cases, the ALT level
rises intermittently, and it is therefore difficult to differenti-
ate the inactive carrier state from the HBeAg-negative CHB
state over a short observation period (28). Thus, HBeAg-neg-
ative patients with normal ALT levels are not always inactive
HBsAg carriers.
In conclusion, serum HBV DNA levels differ significantly
between HBeAg-negative CHB patients and inactive HBsAg
carriers. Serum HBV DNA levels may be an important fac-
tor in clinically differentiating HBeAg-negative CHB cases
from inactive HBsAg carriers. However, the ranges of the
serum HBV levels overlap too widely to allow the definition
of a discriminating cut-off value.
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